Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Elanco Animal Health
ELAN
Elanco Animal Health
Global Animal Protein Demand Will Drive Breakthroughs Amid Regulatory Risks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
02 Aug 25
Updated
02 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$18.00
1.2% undervalued
intrinsic discount
02 Aug
US$17.79
1Y
16.8%
7D
1.5%
Loading
1Y
16.8%
7D
1.5%
Author's Valuation
US$18.0
1.2% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$18.0
1.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-1b
5b
2015
2017
2019
2021
2023
2025
2027
2028
Revenue US$5.2b
Earnings US$210.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.15%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$210.41m
Earnings '28
x
51.84x
PE Ratio '28
=
US$10.91b
Market Cap '28
US$10.91b
Market Cap '28
/
503.68m
No. shares '28
=
US$21.66
Share Price '28
US$21.66
Share Price '28
Discounted to 2025 @ 6.40% p.a.
=
US$17.98
Fair Value '25